The CRISPR Licensing Landscape

@LSPN May 3-4th, 2023, Boston MA

Contact Michael.Arciero@ersgenomics.com for more information.

favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology.
 Our founder, Dr. Emmanuelle Charpentier  won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

CRISPR/Cas9 has transformed the field of gene editing. 
At ERS, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 

Michael Arciero, VP IP & Commercial Development with ERS Genomics will speak at this year’s Life Sciences Patent Network (LSPN) in Boston, May 3-4. 

Attend this session to understand:

1. The current CRISPR Licensing Landscape

2. Common misperceptions: Fact vs. Fction

3. The patent batttle – what’s next?

4. Do you need a license?

5. Regional differences – what geolocation means for your licensing requirements.


CRISPR/Cas9 is a patented invention, so any commerical use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape is clearer than you might think.

Contact Michael.Arciero@ersgenomics.com to secure your CRISPR/Cas9 license.

 

Schedule time with:

Michael Arciero, Vice President IP & Commercial Development

‘This is a lot of misinformation in circulation when it comes to the CRISPR licensing landscape. In speaking at LSPN, my goal is to cut through the noise and provide straightforward answers to common misperceptions.’

Licensing

Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering Dublin, Ireland, and Rome, Italy, 20 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9.

Read Full Article

ERS Genomics appoints John E Milad as Chief Executive Officer

Dublin, Ireland, 13 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology.

Read Full Article

Update: Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

Patent Upheld by China National Intellectual Property Administration Dublin, Ireland, 26 March 2024: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in.

Read Full Article